Invesaro

Stocks Comparison

Dexcom vs 3M: revenue, profit, margins and growth compared

Dexcom brought in $4.7B of revenue in fiscal 2025, 3M $24.9B in fiscal 2025. Revenue changed by +15.6% at Dexcom and +1.5% at 3M on the year before, so Dexcom grew faster. Dexcom kept 17.9% of its revenue as net profit, 3M 13.0%. Free cash flow was $1.1B at Dexcom and $1.4B at 3M.

Side by side, latest fiscal year

DXCMMMM
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$4.7B$24.9B
Revenue growth+15.6%+1.5%
Net income$836.3M$3.3B
Net margin17.9%13.0%
Free cash flow$1.1B$1.4B
Free cash flow margin23.1%5.6%
Earnings per share (diluted)$2.09$6.00
Cash$917.7M$5.2B
Debtn/a$12.6B
Price to earnings41.428.3
Market value$32.7B$87.4B
Dividend yieldn/a1.72%
Rank by revenue in sector#65 of 523 · Health care#25 of 523 · Health care

Over the years

Revenue
DXCM FY2018: $1BDXCM FY2019: $1.5BDXCM FY2020: $1.9BDXCM FY2021: $2.4BDXCM FY2022: $2.9BDXCM FY2023: $3.6BDXCM FY2024: $4BDXCM FY2025: $4.7BMMM FY2018: $32.8BMMM FY2019: $32.1BMMM FY2020: $32.2BMMM FY2021: $35.4BMMM FY2022: $26.2BMMM FY2023: $24.6BMMM FY2024: $24.6BMMM FY2025: $24.9BFY18FY19FY20FY21FY22FY23FY24FY25
DXCM $4.7BMMM $24.9B
Net income
DXCM FY2018: -$127.1MDXCM FY2019: $101.1MDXCM FY2020: $549.7MDXCM FY2021: $216.9MDXCM FY2022: $341.2MDXCM FY2023: $541.5MDXCM FY2024: $576.2MDXCM FY2025: $836.3MMMM FY2018: $5.3BMMM FY2019: $4.5BMMM FY2020: $5.4BMMM FY2021: $5.9BMMM FY2022: $5.8BMMM FY2023: -$7BMMM FY2024: $4.2BMMM FY2025: $3.3BFY18FY19FY20FY21FY22FY23FY24FY25
DXCM $836.3MMMM $3.3B
Net margin
DXCM FY2018: -12.3%DXCM FY2019: 6.8%DXCM FY2020: 28.5%DXCM FY2021: 8.9%DXCM FY2022: 11.7%DXCM FY2023: 14.9%DXCM FY2024: 14.3%DXCM FY2025: 17.9%MMM FY2018: 16.3%MMM FY2019: 14.1%MMM FY2020: 16.9%MMM FY2021: 16.7%MMM FY2022: 22.1%MMM FY2023: -28.4%MMM FY2024: 17.0%MMM FY2025: 13.0%FY18FY19FY20FY21FY22FY23FY24FY25
DXCM 17.9%MMM 13.0%
Revenue growth
DXCM FY2019: +43.1%DXCM FY2020: +30.5%DXCM FY2021: +27.1%DXCM FY2022: +18.8%DXCM FY2023: +24.5%DXCM FY2024: +11.3%DXCM FY2025: +15.6%MMM FY2019: -1.9%MMM FY2020: +0.1%MMM FY2021: +9.9%MMM FY2022: -26.0%MMM FY2023: -5.9%MMM FY2024: -0.1%MMM FY2025: +1.5%FY19FY20FY21FY22FY23FY24FY25
DXCM +15.6%MMM +1.5%
Free cash flow
DXCM FY2018: $56.1MDXCM FY2019: $134.5MDXCM FY2020: $276.6MDXCM FY2021: $53.3MDXCM FY2022: $304.7MDXCM FY2023: $511.9MDXCM FY2024: $630.7MDXCM FY2025: $1.1BMMM FY2018: $4.9BMMM FY2019: $5.4BMMM FY2020: $6.6BMMM FY2021: $5.9BMMM FY2022: $3.8BMMM FY2023: $5.1BMMM FY2024: $638MMMM FY2025: $1.4BFY18FY19FY20FY21FY22FY23FY24FY25
DXCM $1.1BMMM $1.4B

Fiscal years as each company reports them; the two may end in different months.

Questions about Dexcom and 3M

Which is bigger by revenue, Dexcom or 3M?

3M is bigger by revenue: $24.9B in fiscal 2025, against $4.7B for Dexcom in fiscal 2025.

Which keeps more of its revenue as profit, Dexcom or 3M?

Dexcom had a net margin of 17.9% in fiscal 2025; 3M had 13.0% in fiscal 2025.

Which grew revenue faster, Dexcom or 3M?

In their latest fiscal years revenue changed by +15.6% at Dexcom and +1.5% at 3M.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies